

1           **Arterial hypertension and  $\beta$ -amyloid accumulation have**  
2           **spatially overlapping effects on posterior white matter**  
3           **hyperintensity volume: A cross-sectional study**

4   Jose Bernal<sup>1,2,T</sup>, Stefanie Schreiber<sup>2,3,T</sup>, Inga Menze<sup>1,2</sup>, Anna Ostendorf<sup>1</sup>, Malte Pfister<sup>3</sup>, Jonas  
5   Geisendörfer<sup>3</sup>, Aditya Nemali<sup>1,2</sup>, Anne Maass<sup>2</sup>, Renat Yakupov<sup>2</sup>, Oliver Peters<sup>4,5</sup>, Lukas  
6   Preis<sup>5</sup>, Luisa Schneider<sup>5</sup>, Ana Lucia Herrera<sup>5</sup>, Josef Priller<sup>4,6,7,8</sup>, Eike Jakob Spruth<sup>4,6</sup>, Slawek  
7   Altenstein<sup>4,6</sup>, Anja Schneider<sup>9,10</sup>, Klaus Fliessbach<sup>9,10</sup>, Jens Wiltfang<sup>11,12,13</sup>, Björn  
8   H.Schott<sup>11,12</sup>, Ayda Rostamzadeh<sup>14</sup>, Wenzel Glanz<sup>1</sup>, Katharina Buerger<sup>16,17</sup>, Daniel  
9   Janowitz<sup>17</sup>, Michael Ewers<sup>16,17</sup>, Robert Perneczky<sup>18,19,20,21,33</sup>, Boris-Stephan Rauchmann<sup>19</sup>,  
10   Stefan Teipel<sup>22,23</sup>, Ingo Kilimann<sup>22,23</sup>, Christoph Laske<sup>24,25</sup>, Matthias H. Munk<sup>24,26</sup>, Annika  
11   Spottke<sup>9,10</sup>, Nina Roy<sup>9</sup>, Laura Dobisch<sup>2</sup>, Peter Dechent<sup>27</sup>, Klaus Scheffler<sup>28</sup>, Stefan Hetzer<sup>29</sup>,  
12   Steffen Wolfsgruber<sup>9,10</sup>, Luca Kleineidam<sup>9,10</sup>, Matthias Schmid<sup>9, 30</sup>, Moritz Berger<sup>30</sup>, Frank  
13   Jessen<sup>9,14,15</sup>, Miranka Wirth<sup>31</sup>, Emrah Düzel<sup>1,2,32,†</sup>, Gabriel Ziegler<sup>1,2,†</sup>

14   <sup>T</sup> **Shared first authorship**

15   <sup>†</sup> **Shared last authorship**

16   **Author affiliations:**

17   <sup>1</sup>Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University  
18   Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany

19   <sup>2</sup>German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44,  
20   39120 Magdeburg, Germany

21   <sup>3</sup>Department of Neurology, University Hospital Magdeburg, Medical Faculty, Leipziger Str.  
22   44, 39120 Magdeburg, Germany

23 <sup>4</sup>German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

24 <sup>5</sup>Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and  
25 Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany

26 <sup>6</sup>Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 Berlin,  
27 Germany

28 <sup>7</sup>School of Medicine, Technical University of Munich; Department of Psychiatry and  
29 Psychotherapy, Munich, Germany

30 <sup>8</sup>University of Edinburgh and UK DRI, Edinburgh, UK

31 <sup>9</sup>German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1,  
32 53127 Bonn, Germany

33 <sup>10</sup>University of Bonn Medical Center, Dept. of Neurodegenerative Disease and Geriatric  
34 Psychiatry/Psychiatry, Venusberg-Campus 1, 53127 Bonn, Germany

35 <sup>11</sup>German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany

36 <sup>12</sup>Department of Psychiatry and Psychotherapy, University Medical Center Goettingen,  
37 University of Goettingen, Von-Siebold-Str. 5, 37075 Goettingen

38 <sup>13</sup>Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of  
39 Medical Sciences, University of Aveiro, Aveiro, Portugal

40 <sup>14</sup>Department of Psychiatry, University of Cologne, Medical Faculty, Kerpener Strasse 62,  
41 50924 Cologne, Germany

42 <sup>15</sup>Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD),  
43 University of Cologne, Joseph-Stelzmann-Strasse 26, 50931 Köln, Germany

44 <sup>16</sup>German Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-Strasse  
45 17, 81377 Munich, Germany

46 <sup>17</sup>Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich,  
47 Feodor-Lynen-Strasse 17, 81377 Munich, Germany

48 <sup>18</sup>German Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-Strasse  
49 17, 81377 Munich, Germany

50 <sup>19</sup>Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich,  
51 Germany

52 <sup>20</sup>Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany

53 <sup>21</sup>Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College  
54 London, London, UK

55 <sup>22</sup>German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany

56 <sup>23</sup>Department of Psychosomatic Medicine, Rostock University Medical Center, Gehlsheimer  
57 Str. 20, 18147 Rostock

58 <sup>24</sup>German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany

59 <sup>25</sup>Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department  
60 of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany

61 <sup>26</sup>Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany

62 <sup>27</sup>MR-Research in Neurosciences, Department of Cognitive Neurology, Georg-August-  
63 University Goettingen, Germany

64 <sup>28</sup>Department for Biomedical Magnetic Resonance, University of Tübingen, 72076 Tübingen,  
65 Germany

66 <sup>29</sup>Berlin Center for Advanced Neuroimaging, Charité – Universitätsmedizin Berlin, Berlin,  
67 Germany

68 <sup>30</sup>Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn,  
69 Venusberg-Campus 1, D-53127 Bonn

70 <sup>31</sup>German Center for Neurodegenerative Diseases (DZNE), Dresden, Tatzberg 41, 01307  
71 Dresden, Germany

72 <sup>32</sup>Institute of Cognitive Neuroscience, University College London, London, UK

73 <sup>33</sup>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield,  
74 Sheffield, UK

75

76 Correspondence to: Jose Bernal & Miranka Wirth

77 Full address: German Centre for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger  
78 Str. 44, 39120 Magdeburg, Germany & German Centre for Neurodegenerative Diseases  
79 (DZNE), Dresden, Tatzberg 41, 01307 Dresden, Germany

80 E-mail: [jose.bernalmoiano@dzne.de](mailto:jose.bernalmoiano@dzne.de) & [miranka.wirth@dzne.de](mailto:miranka.wirth@dzne.de)

## 81 **Abbreviations**

82 A $\beta$   $\beta$ -amyloid

83 AD Alzheimer's disease

84 ATN Amyloid/Tau/Neurodegeneration

85 B regression coefficient

- 86 CAA Cerebral amyloid angiopathy
- 87 CERAD Consortium to Establish a Registry for Alzheimer's Disease
- 88 CN Non-complaining healthy controls
- 89 CSF Cerebrospinal fluid
- 90 CSVD Cerebral small vessel disease
- 91 FDR False discovery rate
- 92 FLAIR Fluid Attenuated Inversion Recovery
- 93 GM Grey matter
- 94 IQR Interquartile range
- 95 MCI Mild cognitive impairment
- 96 MRI Magnetic resonance imaging
- 97 NC Normal cognition
- 98 PACC5 Preclinical Alzheimer's Cognitive Composite 5
- 99 ROI Region of interest
- 100 SCD Subjective cognitive decline
- 101 SD Standard deviation
- 102 SE Standard error
- 103 SPM Statistical parametric mapping
- 104 TICV Total intracranial volume
- 105 WM White matter

106 WMH White matter hyperintensities

## 107 **Abstract**

### 108 **Background**

109 Posterior white matter hyperintensities (WMH) in subjects across the Alzheimer's disease  
110 (AD) spectrum with minimal vascular pathology suggests that amyloid pathology—not just  
111 arterial hypertension—impacts WMH, adversely influencing cognition. Here we seek to  
112 determine the effect of both hypertension and A $\beta$  positivity on WMH, and their impact on  
113 cognition.

### 114 **Methods**

115 We analysed data from subjects with a low vascular profile and normal cognition (NC),  
116 subjective cognitive decline (SCD), and amnesic mild cognitive impairment (MCI) enrolled  
117 in the ongoing observational multicentre DZNE Longitudinal Cognitive Impairment and  
118 Dementia Study (n=375, median age 70.2 [IQR 66.0-74.4] years; 176 female; NC/SCD/MCI  
119 127/162/86). All subjects underwent a rich neuropsychological assessment. We focused on  
120 baseline memory and executive function—derived from multiple neuropsychological tests  
121 using confirmatory factor analysis—, baseline preclinical Alzheimer's cognitive composite 5  
122 (PACC5) scores, and changes in PACC5 scores over course of three years ( $\Delta$ PACC5).

### 123 **Results**

124 Subjects with hypertension or A $\beta$  positivity presented the largest WMH volumes  
125 ( $p_{FDR}<0.05$ ), with spatial overlap in the frontal (hypertension:  $0.42\pm 0.17$ ; A $\beta$ :  $0.46\pm 0.18$ ),  
126 occipital (hypertension:  $0.50\pm 0.16$ ; A $\beta$ :  $0.50\pm 0.16$ ), parietal lobes (hypertension:  $0.57\pm 0.18$ ;  
127 A $\beta$ :  $0.56\pm 0.20$ ), corona radiata (hypertension:  $0.45\pm 0.17$ ; A $\beta$ :  $0.40\pm 0.13$ ), optic radiation

128 (hypertension:  $0.39\pm 0.18$ ;  $A\beta$ :  $0.74\pm 0.19$ ), and splenium of the corpus callosum  
129 (hypertension:  $0.36\pm 0.12$ ;  $A\beta$ :  $0.28\pm 0.12$ ). Hypertension,  $A\beta$  positivity, and WMH were  
130 connected to cognition. First, WMH coincided with worse cognitive performance and  
131 outcomes ( $p_{FDR}<0.05$ ), regardless of  $A\beta$  and hypertension. Accelerated cognitive decline was  
132 associated with WMH in the genu of the corpus callosum and segments of the forceps major  
133 and inferior fronto-occipital longitudinal fasciculus ( $p_{FDR}<0.05$ ). Second, hypertension was  
134 indirectly linked to cognitive performance at baseline and over time via splenial WMH  
135 (*indirect-only effect*; memory:  $-0.05\pm 0.02$ ,  $p_{FDR}=0.029$ ; executive:  $-0.04\pm 0.02$ ,  $p_{FDR}=0.067$ ;  
136 PACC5:  $-0.05\pm 0.02$ ,  $p_{FDR}=0.030$ ;  $\Delta$ PACC5:  $-0.09\pm 0.03$ ,  $p_{FDR}=0.043$ ). Third, the relationship  
137 between  $A\beta$  positivity and baseline and longitudinal cognitive performance was independent  
138 of WMH burden.

### 139 **Conclusions**

140 Posterior white matter is susceptible to hypertension and  $A\beta$  accumulation and it mediates the  
141 association between hypertension and cognitive dysfunction. Posterior WMH could be a  
142 promising target to tackle the downstream damage related to the potentially interacting and  
143 potentiating effects of the two pathologies.

### 144 **Trial Registration**

145 German Clinical Trials Register (DRKS00007966, 04/05/2015)

146

147 **Keywords:** white matter hyperintensities; vascular risk; Alzheimer's disease; cognitive  
148 performance; MRI

## 149 **Background**

150 The term "cerebral white matter hyperintensities" (WMH) describes dynamic and diffuse  
151 microstructural alterations in both periventricular and deep white matter, which appear  
152 hypodense on computed tomography and hyperintense on T2-weighted magnetic resonance  
153 imaging (MRI) and coincide with demyelination, axon loss, and gliosis [1,2]. WMH are  
154 common—especially but not exclusively in old age—and relate to a large spectrum of  
155 clinical symptoms, including apathy, fatigue, delirium, depression, progressive cognitive  
156 impairment, physical function disturbances, and increased risk of dementia and stroke [2,3].

157 Alterations to the functioning of cerebral micro-vessels—also known as cerebral small vessel  
158 disease (CSVD)—caused, for instance, by long-term exposure to cardiovascular risk factors  
159 (hypertension particularly) have been assumed to drive WMH formation [4–6]. Nonetheless,  
160 recent studies demonstrating elevated global and posterior WMH in patients along the  
161 Alzheimer's disease (AD) spectrum with minimal vascular pathology (for review see [1,7–9])  
162 call into question the assumption that any "AD-related" WMH solely reflect a vascular  
163 contribution. This viewpoint has also been challenged by studies reporting a more "AD-like"  
164 WMH pattern in A $\beta$  positive subjective cognitive decline (SCD), mild cognitive impairment  
165 (MCI) or AD. The "AD-like" pattern is roughly confined to deep and periventricular posterior  
166 regions comprising the (parieto-)occipital lobe, corona radiata, optic (thalamic) radiation, or  
167 the corpus callosum (especially splenium) and presents neuropathologically with underlying  
168 gliosis, and axonal and myelin loss, but minimal vascular pathology—likely occurring  
169 secondary to cortical neurodegeneration [7–10]. Further studies demonstrate frontal or  
170 temporoparietal WMH dominance in AD as well and others report mixed results on the  
171 relationship between posterior WMH and AD pathology [11–14]. "WMH of presumed



172 vascular origin" are, however, usually depicted in deep and periventricular frontal areas,  
173 suggesting some spatial WMH heterogeneity in hypertension compared to AD [8,15].

174 Here we use region- and voxel-based lesion analysis to determine the effect of both  
175 hypertension and AD pathology, i.e.  $\beta$ -amyloid ( $A\beta$ ) positivity, on WMH as well as their  
176 interacting impact on cognition. For that purpose, we study WMH of non-demented  
177 participants of a large multicentre cohort with available cerebrospinal fluid (CSF) AD  
178 biomarkers, history of hypertension, and cross-sectional as well as longitudinal  
179 neuropsychological tests.

## 180 **Methods**

### 181 **Study design**

182 We used baseline MRI, CSF AD biomarkers, cognitive performance scores, medical records  
183 and longitudinal cognitive performance scores from the DELCODE (DZNE Longitudinal  
184 Cognitive Impairment and Dementia Study) cohort, an observational multicentre study from  
185 the German Centre for Neurodegenerative Diseases (DZNE) that focuses on the multimodal  
186 assessment of preclinical and clinical AD stages [16]. All participants received an extensive  
187 assessment at the local study site prior to joining DELCODE, which included medical  
188 history, psychiatric and neurological examination, neuropsychological testing, blood  
189 laboratory work-up, and routine MRI in accordance with local standards. All memory clinics  
190 used the Consortium to Establish a Registry for Alzheimer's Disease (CERAD)  
191 neuropsychological test battery [17] to assess cognitive function. We focused on non-  
192 complaining healthy controls with normal cognition (NC) and participants with SCD and

193 MCI and excluded patients with dementia due to AD to enrich our sample by variance due to  
194 vascular disease and A $\beta$  pathology.

195 The presence of SCD and amnesic MCI was diagnosed using the existing research criteria  
196 for SCD [18,19] and MCI [20], respectively. Participants were diagnosed with SCD if they  
197 reported subjective cognitive decline or memory concerns, as expressed to the physician of  
198 the memory centre, and had a test performance better than -1.5 standard deviations (SD)  
199 below the age, sex, and education-adjusted normal performance on all subtests of the  
200 CERAD battery. The MCI group consisted of participants with amnesic MCI, as defined by  
201 age, sex, and education-adjusted performance below -1.5 SD on the delayed recall trial of the  
202 CERAD word-list episodic memory tests.

203 The NC group was recruited through local newspaper advertisements. Individuals who  
204 responded to the advertisement were screened by telephone with regard to SCD. The control  
205 group had to achieve unimpaired cognitive performance according to the same definition as  
206 the SCD group.

207 All participants entered DELCODE based on either their clinical diagnosis derived from the  
208 clinical workup or their identification as a control subject according to the procedures  
209 outlined. Additional inclusion criteria for all groups were age  $\geq$  60 years, fluent German  
210 language skills, capacity to provide informed consent, and presence of a study partner. The  
211 main exclusion criteria for all groups were conditions clearly interfering with participation in  
212 the study or the study procedures, including significant sensory impairment. The following  
213 medical conditions were considered exclusion criteria: current major depressive episode,  
214 major psychiatric disorders either at baseline or in the past (e.g., psychotic disorder, bipolar  
215 disorder, substance abuse), neurodegenerative disorder other than AD, vascular dementia,  
216 history of stroke with residual clinical symptoms, history of malignant disease, severe or

217 unstable medical conditions, and clinically significant laboratory abnormalities in vitamin  
218 B12. Prohibited drugs included chronic use of psychoactive compounds with sedative or  
219 anticholinergic effects, use of anti-dementia agents in SCD, amnesic MCI, and control  
220 subjects, and investigational drugs for the treatment of dementia or cognitive impairment one  
221 month before entry and throughout the duration of the study.

222 All participants gave written informed consent before inclusion in the study. DELCODE is  
223 retrospectively registered at the German Clinical Trials Register (DRKS00007966,  
224 04/05/2015) and was approved by ethical committees and local review boards.

## 225 **Hypertension**

226 Medical records were retrospectively screened for cardiovascular risk factors at the time of  
227 MRI. Patients diagnosed before to have primary or secondary arterial hypertension were  
228 considered to suffer from arterial hypertension (1: hypertensive; 0: normotensive). Single  
229 blood pressure measurements were not taken into account since repeated, long-term or at-  
230 home measurements would be required for the final diagnosis [21].

## 231 **Cognitive performance**

232 All participants underwent a rich neuropsychological assessment, comprising the Mini-  
233 Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale–Cognitive 13-  
234 item subscale (ADAS-Cog 13), the Free and Cued Selective Reminding Test (FCRST;  
235 including a serial subtraction task, Wechsler Memory Scale revised version (WMS-R),  
236 Logical Memory [Story A] and Digit Span), two semantic fluency tasks (animals and  
237 groceries), the Boston Naming Test (15-item short version analogue to the CERAD battery,  
238 supplemented by five infrequent items from the long version), the oral form of the Symbol-  
239 Digit-Modalities Test (including a subsequent free recall of symbols and symbol-digit

240 pairings), Trail Making Test Parts A and B, Clock Drawing and Clock Copying, a recall task  
241 of previously copied figures (as in the CERAD test battery), the Face Name Associative  
242 Recognition Test, and a Flanker task to assess executive control of attention. We focused on  
243 memory and executive function at baseline derived from these neuropsychological tests using  
244 confirmatory factor analysis to reduce the influence of test-specific effects and measurement  
245 errors [22].

246 We also leveraged the Preclinical Alzheimer’s Disease Cognitive Composite (PACC5) [23],  
247 which provides a single outcome measure reflective of episodic memory, timed executive  
248 function, and global cognition; domains that have been found sensitive to amyloid pathology.  
249 The PACC5 score was calculated as the mean of an individual’s z-standardised performance  
250 in the FCSRT Free Recall and Total Recall, the MMSE, the WMS-R Logical Memory Story  
251 A Delayed Recall, the Symbol-Digit-Modalities Test, and the sum of the two category  
252 fluency tasks and used the baseline mean and SD values of the cognitively unimpaired group  
253 of our sample to derive the subtest z-scores.

254 We selected subjects with available PACC5 scores over three annual follow-ups for further  
255 analysis. We estimated rates of change in these PACC5 scores over time using a linear mixed  
256 effect model ( $\Delta$ PACC5 from hereon). We expressed it as follows:

$$PACC5_{ij} = X_{ij}\beta + Z_{ij} b_i + \epsilon_{ij}, \quad (1)$$

257 where  $PACC5_{ij}$  is the PACC5 scores of subject  $i \in [1, N]$  at visit  $j \in [1, t]$ ;  $X_{ij} \in \mathbb{R}^{N \times p}$  a  
258 matrix of the  $p$  predictor variables;  $\beta \in \mathbb{R}^p$  a vector of fixed-effects regression coefficients;  
259  $Z_{ij} \in \mathbb{R}^{N \times q}$  a design matrix for the  $q$  random effects;  $b_i \in \mathbb{R}^q$  a vector of random effects; and  
260  $\epsilon_{ij}$  the within-subject measurement errors. The fixed effects structure include clinical group  
261 structure measured at baseline and their corresponding interaction with time ( $t_{ij}$ ). The fixed  
262 effects include age, sex and education taken at baseline.

## 263 **Structural MRI**

264 Structural MRI scans were acquired at nine German DZNE sites on Siemens MR scanners  
265 (including three TIM Trio, four Verio, one Skyra, and one Prisma system). We used T1-  
266 weighted MPRAGE images (3D GRAPPA PAT 2, 1 mm<sup>3</sup> isotropic, 256 × 256, 192 sagittal  
267 slices, repetition time 2500 ms, echo time 4.33 ms, inversion time 1100 ms, flip angle 7°, ~5  
268 min acquisition time) and T2-weighted 3D FLAIR images (GRAPPA PAT factor 2, 1 mm<sup>3</sup>  
269 isotropic, 256 × 256, 192 sagittal slices, repetition time 5000 ms, echo time 394 ms, inversion  
270 time 1800 ms, ~7 min acquisition time). Standard operating procedures, quality assurance  
271 and assessment were provided and supervised by the DZNE imaging network (iNET,  
272 Magdeburg) as described in [16]. We computed the mean background intensity as a surrogate  
273 measure of image quality and motion artefacts [24,25] and adjusted statistical models for it,  
274 as the quality of the scans determine also segmentation performance [26–28].

## 275 **Biomarker characterisation**

276 Trained study assistants carried out lumbar punctures for 49% of all DELCODE participants.  
277 CSF samples were centrifuged, aliquoted and stored at -80°C for retests. Biomarkers known  
278 to mirror AD pathology (CSF Aβ<sub>42</sub> and Aβ<sub>40</sub>) were determined by commercially available  
279 kits (V-PLEX Aβ Peptide Panel 1 (6E10) Kit (K15200E)). Each participant was classified as  
280 normal (-) or abnormal (+) with regard to amyloid levels based on the Aβ<sub>42/40</sub> ratio,  
281 independently of their phosphorylated Tau (pTau) status, in line with the ATN classification  
282 system. Cut-offs (Aβ negative: Aβ<sub>42/40</sub> >0.08; Aβ positive: Aβ<sub>42/40</sub> ≤ 0.08) were calculated  
283 from DELCODE using the Gaussian mixture modelling in the R-package flexmix (v2.3-15)  
284 (for details see [16,29]).

## 285 **WMH segmentation and spatial processing**

286 We processed baseline T1-weighted and FLAIR scans as follows. We performed bias field  
287 inhomogeneity correction, skull stripping, and segmentation using the Multi-Brain (MB)  
288 toolbox in statistical parametric mapping (SPM) [30]. We segmented grey matter (GM),  
289 white matter (WM), and CSF from T1-weighted scans with MB and identified WMH  
290 probability maps from FLAIR scans using the Lesion Prediction Algorithm in the Lesion  
291 Segmentation Toolbox [31]. We then used MB for normalising tissue classes (and WMH  
292 maps) to a DELCODE-specific MB template. We adjusted for local volume changes  
293 introduced by the normalisation in GM and WMH probability maps by modulation with  
294 Jacobian determinants [30,32]. Finally, we smoothed WMH maps with Gaussian kernels (6  
295 mm full width at half maximum). Processing results of all steps were carefully checked  
296 visually and statistically using covariance-based tools provided in Computational Anatomy  
297 Toolbox 12 (CAT12) [33].

## 298 **ROI-based processing**

299 We extracted WMH volume from 12 regions of interest (ROI) in cerebral WM, as described  
300 in detail in a previous study [11]. In brief, we created ROIs in accordance with the STRIVE  
301 criteria [34] and included the four lobes of the brain, four major WM tracks and three  
302 sections of the corpus callosum and a global cerebral WM mask. We calculated WMH  
303 volumes for each ROI and adjusted for total intracranial volume (TICV). All computations  
304 were conducted in the template space.

305 A schematic overview both processing and analysis methods is illustrated in **Figure S1**.

## 306 **Statistical analyses**

### 307 **Relationship between hypertension and A $\beta$ positivity**

308 We tested for associations between hypertension and A $\beta$  positivity given their potential  
309 collinearity [35–38] using the Pearson's Chi-squared test with Yates' continuity correction in  
310 the R-package *stats* (v3.6.2).

### 311 **Effects of hypertension and A $\beta$ positivity on WMH**

312 We hypothesised that a history of hypertension and an abnormal build-up of A $\beta$  relate  
313 positively to the volume of WMH, but that both conditions display distinct spatial effects:  
314 hypertension on deep and periventricular frontal regions and A $\beta$  on deep and periventricular  
315 posterior regions, as discussed in the literature [1,4–9]. We used a 2 $\times$ 2 ANCOVA model in  
316 CAT12 to examine the relationship between WMH segmentation maps (outcome) and  
317 hypertension and A $\beta$  (factors) at a voxel level. Similarly, to probe the same relationship at an  
318 ROI level, we built 2 $\times$ 2 ANCOVA models in R (*stats*, v3.6.2), one for each region of interest  
319 separately. We controlled for covariates and confounders (see '*Covariates, confounders, and*  
320 *data transformation*' below).

### 321 **Effects of WMH on cognitive performance**

322 Our hypothesis was that cognitive performance declined and rates of change in cognition  
323 increased as voxel-wise and regional WMH increased, in agreement with previous findings  
324 [2,3]. For voxel-based analysis, we used multiple linear regression in CAT12 with WMH  
325 segmentation maps as the dependent variable and cognitive performance as the independent  
326 variable. Likewise, for each region of interest, we also used multiple linear regression in R  
327 (*stats*, v3.6.2) to probe the relationship between regional WMH volume and cognition. We  
328 created different models with memory, executive function, PACC5, and  $\Delta$ PACC5 as

329 dependent variables. Note that, for studying the effect of baseline WMH on change in  
330 cognition, we leveraged summary statistics ( $\Delta\text{PACC5}$ ) instead of using a linear mixed effect  
331 model to keep the mass univariate analysis efficient [39] and both the voxel- and region-wise  
332 analyses consistent. We controlled for hypertension and  $\text{A}\beta$  positivity in addition to  
333 covariates and confounders (see ‘*Covariates, confounders, and data transformation*’ below).

### 334 **Mediation models**

335 Assuming that long-term exposure to hypertension and  $\text{A}\beta$  build-up has a negative effect on  
336 the integrity of the white matter and that its damage—depicted in the form of regional  
337 WMH—impacts cognition negatively, we hypothesise that there is an indirect effect of  
338 hypertension and  $\text{A}\beta$  on cognition that is mediated by WMH volume, in line with theoretical  
339 considerations [5,6,40,41] (**Figure 1**). We used the R-package lavaan (v0.6-11) and followed  
340 the steps for mediation analysis suggested by Hair *et al.* [42] Significance was assessed using  
341 95% confidence intervals generated by bias-corrected bootstrap with 1000 replicates.

### 342 **Covariates, confounders, and data transformation**

343 We adjusted all models for covariates (age, sex, years of education) and confounders (TICV)  
344 and mean background intensity to reduce biases brought in by correlated regressors. To  
345 account for collinearity between TICV and sex, we chose "overall mean" as "centring" for  
346 TICV and leveraged global scaling for this confounder. We refrained from adjusting our  
347 analyses for clinical groups to avoid collinearity issues with  $\text{A}\beta$  positivity (namely,  $\text{A}\beta$   
348 positivity was more frequent in MCI vs NC and SCD). We log-transformed regional WMH  
349 volumes to account for skewness.



## 350 **Explicit mask**

351 We used an explicit mask to constrain the analysis to voxels in which data for at least five  
352 patients were available.

## 353 **Correction for multiple comparisons**

354 We adjusted *p*-values for multiple comparisons using the false discovery rates (FDR)  
355 approach to deal with the problem of multiple comparisons.[43]

## 356 **Results**

### 357 **Sample description**

358 We included baseline data of 375 subjects out of 1079 recruited for DELCODE after quality  
359 control and assessing the availability of CSF biomarkers and MRI (Figure S2; median age  
360 70.0 [IQR 66.0-74.0] years, 46.9% female, median years of education 13 [IQR 12-17];  
361 European origins). ΔPACC5 was only available for a subset (n=226/375). Demographics and  
362 global WMH volumes stratified by hypertension and Aβ positivity are summarised in **Table**  
363 **1**. We found no significant association between arterial hypertension and Aβ positivity  
364 ( $\chi^2=2.1302$ ,  $p=0.1444$ ).

365 **Table 1 Demographics and WMH volume, stratified by hypertension diagnosis and Aβ positivity (n=375)<sup>a</sup>**

Group	Subjects n (%)	Age in years Median [IQR]	Female n (%)	Education in years Median [IQR]	WMH volume in ml <sup>b</sup> Median [IQR]
Hypertension	202 (53.9)	72 [67, 75]	89 (23.7)	13 [12, 17]	1.87 [0.83, 5.83]
Normotension	173 (46.1)	69 [64, 72]	87 (23.2)	14 [13, 17]	1.19 [0.45, 2.78]
Aβ positive	132 (35.2)	72 [68, 76]	55 (14.7)	13 [12, 17]	2.39 [1.11, 6.32]
Aβ negative	243 (64.8)	68 [65, 73]	121 (32.2)	13 [13, 17]	1.16 [0.55, 2.96]

366  
367  
368  
369  
370  
371  
372

<sup>a</sup>Global WMH volumes are higher subjects with hypertension vs normotension (W=13744,  $p<0.001$ ) and Aβ positive vs negative (W=11851,  $p<0.001$ ); age differences between groups explain, to a certain extent, these outcomes (hypertension vs normotension: W=13014,  $p<0.001$ ; Aβ positive vs Aβ negative: W=10186,  $p<0.001$ )

<sup>b</sup>Unadjusted WMH volumes in ml  
n sample size  
IQR interquartile range

373 **WMH are associated with both arterial hypertension and A $\beta$**   
 374 **positivity**

375 We initially investigated WMH in relation to hypertension and A $\beta$  positivity. We observed  
 376 that the global volume of WMH was a fourth greater in subjects with either a history of  
 377 hypertension vs normotension (26% [95%-CI 5%, 52%]) or a positive vs negative A $\beta$  status  
 378 (25% [95%-CI 3%, 52%]) (**Table 2**). Regional variations in the frontal, parietal, and  
 379 occipital—not temporal—lobes contributed to this outcome; regression coefficients for both  
 380 hypertension and A $\beta$  positivity were comparable in these three regions (**Table 2**). In posterior  
 381 regions of the brain, we found that the relationship between WMH and hypertension was  
 382 clearer than that between WMH and A $\beta$  positivity in the splenium of the corpus callosum  
 383 (**Figure 2** and **Table 2**); the opposite was true in the optic radiation (**Figure 2** and **Table 2**;  
 384 peak: between forceps major and inferior fronto-occipital fasciculus).

385 **Table 2. Subjects with hypertension and A $\beta$  positivity present the largest frontal, parietal, and occipital WMH volumes<sup>b</sup>**

	WMH volume <sup>a</sup>	Hypertension		A $\beta$ positivity	
		B (SE)	<i>p</i> <sub>FDR</sub>	B (SE)	<i>p</i> <sub>FDR</sub>
	Global	<b>0.23 (0.09)</b>	<b>0.030</b>	<b>0.22 (0.10)</b>	<b>0.044</b>
Lobes	Frontal	<b>0.42 (0.17)</b>	<b>0.021</b>	<b>0.46 (0.18)</b>	<b>0.021</b>
	Temporal	0.14 (0.14)	0.447	0.22 (0.15)	0.268
	Occipital	<b>0.50 (0.16)</b>	<b>0.003</b>	<b>0.50 (0.16)</b>	<b>0.004</b>
	Parietal	<b>0.57 (0.18)</b>	<b>0.005</b>	<b>0.56 (0.20)</b>	<b>0.008</b>
Tracts	Corona radiata	<b>0.45 (0.17)</b>	<b>0.020</b>	<b>0.40 (0.13)</b>	<b>0.046</b>
	External capsule	0.21 (0.13)	0.171	0.27 (0.13)	0.096
	Internal capsule	0.22 (0.14)	0.209	0.07 (0.15)	0.741
	Optic radiation	<b>0.39 (0.18)</b>	<b>0.041</b>	<b>0.74 (0.19)</b>	<b>0.001</b>
Corpus callosum	Genu	0.23 (0.11)	0.087	0.07 (0.12)	0.641
	Body	0.21 (0.10)	0.053	0.15 (0.10)	0.212
	Splenium	<b>0.36 (0.12)</b>	<b>0.005</b>	<b>0.28 (0.12)</b>	<b>0.038</b>

386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394

<sup>a</sup>We log-transformed WMH volumes to deal with skewness

<sup>b</sup>We built multiple linear regression models to examine regional WMH volume (outcome) in relation to hypertension and A $\beta$  positivity (factors)—one for each region of interest separately. We controlled for age, sex, education, mean background intensity, and total intracranial volume. We print *p*<sub>FDR</sub> < 0.05 in bold.

*p*<sub>FDR</sub> *p*-values after adjusting for multiple comparisons using FDR

B regression coefficient

SE standard error

395 **WMH are negatively associated with cognitive performance and**  
 396 **outcomes**

397 We then investigated whether cognitive performance and outcomes were associated with  
 398 WMH (**Figure 3** and **Table 3**). We found a significant association between global WMH  
 399 volumes and worse baseline cognitive performance and a sharper cognitive decline over the  
 400 course of three years, regardless of hypertension diagnosis and A $\beta$  positivity (**Table 3**).  
 401 Evidence for such a connection was present in most regions of interest, except in the external  
 402 capsule. Such relationships were consistently evident around portions of the anterior thalamic  
 403 radiation neighbouring the thalamus (**Figure 3**). In frontal and occipital regions, we also saw  
 404 a significant link between WMH and quicker cognitive deterioration (**Figure 3** - frontal peak  
 405 at the level of the genu of the corpus callosum; occipital peak at the level of the forceps major  
 406 and inferior fronto-occipital longitudinal fasciculus).

407 **Table 3. Higher WMH volumes are associated with worse and worsening cognitive performance<sup>b</sup>**

WMH volume <sup>a</sup>	Baseline (n=375)			Longitudinal (n=226)		
	Memory	Executive	PACC5	$\Delta$ PACC5		
	B (SE); <i>p</i> <sub>FDR</sub>	B (SE); <i>p</i> <sub>FDR</sub>	B (SE); <i>p</i> <sub>FDR</sub>	B (SE); <i>p</i> <sub>FDR</sub>		
Global	<b>-0.10 (0.03); &lt;0.001</b>	<b>-0.08 (0.03); 0.005</b>	<b>-0.10 (0.03); 0.001</b>	<b>-0.16 (0.05); 0.001</b>		
Lobes	Frontal	<b>-0.04 (0.05); 0.012</b>	<b>-0.03 (0.02); 0.028</b>	<b>-0.04 (0.02); 0.008</b>	<b>-0.09 (0.03); 0.004</b>	
	Temporal	<b>-0.07 (0.02); 0.001</b>	<b>-0.05 (0.02); 0.007</b>	<b>-0.07 (0.02); &lt;0.001</b>	<b>-0.13 (0.04); &lt;0.001</b>	
	Occipital	<b>-0.04 (0.02); 0.006</b>	-0.02 (0.02); 0.335	-0.03 (0.02); 0.078	<b>-0.10 (0.03); 0.001</b>	
	Parietal	<b>-0.04 (0.01); 0.002</b>	<b>-0.03 (0.01); 0.040</b>	<b>-0.04 (0.01); 0.005</b>	<b>-0.06 (0.03); 0.025</b>	
	Corona radiata	<b>-0.05 (0.01); 0.001</b>	<b>-0.04 (0.02); 0.008</b>	<b>-0.05 (0.02); 0.003</b>	<b>-0.08 (0.03); 0.004</b>	
Tracts	External capsule	-0.03 (0.02); 0.142	-0.00 (0.02); 0.893	-0.03 (0.02); 0.107	-0.07 (0.04); 0.103	
	Internal capsule	<b>-0.05 (0.02); 0.004</b>	<b>-0.05 (0.02); 0.005</b>	<b>-0.06 (0.02); 0.002</b>	<b>-0.08 (0.03); 0.016</b>	
	Optic radiation	<b>-0.05 (0.01); 0.001</b>	-0.02 (0.01); 0.198	<b>-0.04 (0.01); 0.010</b>	<b>-0.09 (0.03); 0.001</b>	
Corpus callosum	Genu	<b>-0.07 (0.02); 0.004</b>	-0.04 (0.02); 0.057	<b>-0.06 (0.02); 0.016</b>	<b>-0.11 (0.04); 0.004</b>	
	Body	<b>-0.11 (0.03); &lt;0.001</b>	<b>-0.10 (0.03); &lt;0.001</b>	<b>-0.11 (0.03); &lt;0.001</b>	<b>-0.16 (0.05); 0.001</b>	
	Splenium	<b>-0.10 (0.02); &lt;0.001</b>	<b>-0.08 (0.02); 0.001</b>	<b>-0.10 (0.02); &lt;0.001</b>	<b>-0.13 (0.04); 0.002</b>	

408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418

<sup>a</sup>We log-transformed WMH volumes to deal with skewness

<sup>b</sup>For each region of interest, we used multiple linear regression to probe the relationship between regional WMH volume and cognitive performance. We created different models with baseline (memory, executive function, and PACC5) and longitudinal ( $\Delta$ PACC5) cognitive performance as dependent variables. We adjusted for hypertension, A $\beta$  positivity, age, sex, education, mean background intensity, and total intracranial volume. We print *p*<sub>FDR</sub> < 0.05 in bold.

*p*<sub>FDR</sub> *p*-values after adjusting for multiple comparisons using FDR

n sample size

B regression coefficient

SE standard error

419 **The effect of A $\beta$  positivity on cognition does not depend on WMH,**  
420 **but that of hypertesion does**

421 Our final assessment consisted of determining whether A $\beta$  positivity or hypertension were  
422 associated with cognition (**Table 4**). Despite the lack of evidence for a direct association  
423 between hypertension and cognitive performance, we found hypertension to be indirectly  
424 linked to both worse performance at baseline and a steeper deterioration over the course of  
425 three years via splenial WMH (regression coefficient  $\pm$  standard error; memory:  $-0.05 \pm 0.02$ ,  
426  $p_{FDR}=0.029$ ; executive:  $-0.04 \pm 0.02$ ,  $p_{FDR}=0.067$ ; PACC5:  $-0.05 \pm 0.02$ ,  $p_{FDR}=0.030$ ;  $\Delta$ PACC5:  
427  $-0.09 \pm 0.03$ ,  $p_{FDR}=0.043$ ). On the other hand, the association between A $\beta$  positivity and  
428 baseline and longitudinal cognitive performance (memory:  $-0.33 \pm 0.08$ ,  $p_{FDR}<0.001$ ;  
429 executive:  $-0.21 \pm 0.08$ ,  $p_{FDR}<0.001$ ; PACC5:  $-0.29 \pm 0.09$ ,  $p_{FDR}=0.006$ ;  $\Delta$ PACC5:  $-0.34 \pm 0.04$ ,  
430  $p_{FDR}<0.05$ ) was independent of its association with regional WMH volumes (no grounds for  
431 mediation in general, as shown in **Table 2**).

432 **Discussion**

433 Using data from a large multi-site cohort of older adults along the AD spectrum (n=375), we  
434 investigated the impact of arterial hypertension and A $\beta$  positivity on WMH and cognition.  
435 Our data suggest that (i) both hypertension and A $\beta$  positivity are associated with increased  
436 volume of WMH at both voxel and regional levels, (ii) WMH are strongly associated with  
437 poor cognitive performance and outcomes, (iii) posterior WMH have a role in the association  
438 between hypertension and cognitive performance at baseline and over time, and (iv) the  
439 relationship between A $\beta$  positivity and cognition does not depend on WMH.  
440 We observed a posterior WMH dominance in A $\beta$ -positive older adults in the predementia  
441 stage of the AD continuum. Global and posterior WMH presence and volume were

442 nonetheless the largest when both A $\beta$  retention and hypertension occurred simultaneously  
443 and the smallest when none of them did. The posterior white matter could therefore be  
444 considered vulnerable to the independent yet interacting and potentiating effects of AD  
445 pathology and hypertension-related CSVD. One could thus consider posterior WMH to be a  
446 structural correlate that underlies the common observations that vascular disease, in particular  
447 hypertension, lowers the threshold for all-cause dementia development in face of pre-existing  
448 AD pathology, and vice versa [4–6]. As posterior WMH dominance could also relate to  
449 cerebrovascular deposition of A $\beta$ , i.e. cerebral amyloid angiopathy (CAA), a condition that  
450 highly overlaps with AD pathology (for review see [44,45]), we visually inspected  
451 susceptibility-weighted sequences of all MRIs. Isolated lobar haemorrhagic markers were  
452 found in less than 10% (of them 19 were diagnosed with possible and 4 with probable CAA  
453 according to the Boston criteria [46,47]) of participants, making a relevant impact of CAA on  
454 posterior WMH in our sample highly unlikely.

455 WMH can negatively impact cognitive function, but associations with memory have been  
456 less consistent compared to associations with executive function (for review see [48]). With  
457 the exception of the external capsule, we found rather substantial evidence for associations  
458 between WMH and worse cognitive performance, likewise affecting memory and executive  
459 function, and outcomes (**Table 3**). Intriguingly, hypertension was associated with executive,  
460 memory, and baseline and longitudinal global cognitive function only via splenial WMH, a  
461 white matter structure responsible for cognitive processing and a hub where distinct  
462 pathologies impact the neural circuitries interconnecting the temporal and occipital regions of  
463 both cerebral hemispheres [7,49–51]. White matter damage in this region, as associated with  
464 cardiovascular risk, could be expected to translate to lower cognitive functioning in global  
465 cognition but also in discrete domains [7]. In previous studies though, posterior/splenial  
466 WMH have been found associated with executive (including attention), but not memory

467 function [7,10]. Differences may arise from WMH quantification methods and/or smaller  
468 sample sizes including AD patients only (not individuals with SCD/MCI), in whom largely  
469 advanced (medial temporal lobe) AD pathology is the major driver for memory decline,  
470 possibly "diluting" concurrent memory effects of posterior WMH.

471 Contrary to our expectations and to strong evidence from large longitudinal population-based  
472 studies (for review see [6]), we did not see a direct effect of hypertension effect on cognition  
473 but rather an indirect-only effect via splenial WMH. This finding might reflect a selection  
474 bias of the DELCODE study: exclusion of individuals with advanced vascular disease, which  
475 would likewise result in the exclusion of those with severe and uncontrolled hypertension.  
476 This constellation, additionally, explains the somewhat lower prevalence of arterial  
477 hypertension (nearly 54% compared to 63%), with a slightly higher number of A $\beta$  positives  
478 (35% compared to a range of 17% to 34%) compared to that in population-based cohorts  
479 aged over 60 years [52–54]. Our definition of arterial hypertension was based on  
480 retrospective screening of medical records for already existing hypertension diagnoses, which  
481 might have missed those participants with recently, i.e. newly, diagnosed hypertension after  
482 baseline MRI, also contributing to lower prevalence.

483 This study has limitations. First, our imaging results are cross-sectional. While our findings  
484 suggest WMH are indeed spatially associated with both hypertension and A $\beta$  positivity, they  
485 do not address causality (e.g. vascular risk first, impaired brain drainage second).  
486 Longitudinal analysis of DELCODE imaging data might provide further insights into the  
487 influence of lifestyle over time and help disentangle the mixed effects observed in this cross-  
488 sectional study. Second, our mediation model investigates whether WMH volume can  
489 mediate the association between A $\beta$  and hypertension on cognitive function. While this  
490 choice was based on a theoretical consideration [5,6,40,41], a model where the AD and  
491 CSVD pathologies (here as A $\beta$  accumulation and WMH burden) cyclically contribute to each

492 other would also be feasible [2,5,55]. Third, the study of WMH probability patterns in other  
493 cohorts of individuals (e.g. whose origins are other than European; DELCODE participants  
494 are predominantly of European origins) with a high vascular but low AD profile or vice versa  
495 could be informative on the mechanisms leading to these findings in a more general way.  
496 Further, we did not consider WMH patterns, which could be punctuated or confluent, for  
497 example, or the clinically established distinction between deep and periventricular WMH.

## 498 **Conclusion**

499 Our work points toward a large spatial overlap between the effect of arterial hypertension and  
500 A $\beta$  build-up on WMH, with both constellations considered risk factors for white matter  
501 damage. At the same time, our work calls into question whether posterior WMH are a core  
502 feature related to AD pathology, alternatively suggesting that posterior white matter is  
503 vulnerable to both vascular and amyloid pathologies. While the effect of A $\beta$  on cognition  
504 would seem rather independent of WMH, posterior WMH seem to play a role in the  
505 association between arterial hypertension and poor cognitive performance and outcomes; it  
506 could be a promising target to tackle the downstream damage related to the interacting and  
507 potentiating effect of multiple pathologies.

## 508 **Declarations**

### 509 **Ethics approval and consent to participate**

510 All participants gave written informed consent before inclusion in the study. DELCODE is  
511 retrospectively registered at the German Clinical Trials Register (DRKS00007966,  
512 04/05/2015) and was approved by ethical committees and local review boards.

## 513 **Consent for publication**

514 Not applicable.

## 515 **Availability of data and materials**

516 The datasets used and analysed during the current study are available from the corresponding  
517 author on reasonable request.

## 518 **Competing interests**

519 The authors report no competing interests.

## 520 **Funding**

521 This research was supported by the German Center for Neurodegenerative Diseases  
522 (Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE; reference number BN012)  
523 and funded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG;  
524 Project IDs 425899996 and 362321501/RTG 2413 SynAGE). The funding bodies played no  
525 role in the design of the study or collection, analysis, or interpretation of data or in writing the  
526 manuscript.

## 527 **Author's contributions**

528 Conceptualisation: JB, SS, MW, GZ. Methodology: JB, SS, MW, GZ. Software: JB, GZ.  
529 Formal analysis: JB. DELCODE study design: ED, AS, and FJ. Image processing: JB, GZ,  
530 RY, MW. Image analysis and modelling: JB, GZ. Investigation: JB, SS, MW, GZ. Writing  
531 original draft preparation: JB, SS, MW, GZ. Writing – review and editing: All authors.



## 532 **Acknowledgements**

533 We would like to express our gratitude to all DELCODE participants. We also thank the  
534 Max-Delbrück-centrum für Molekulare medizin in der Helmholtz-Gemeinschaft (MDC),  
535 Freie Universität Berlin Center for Cognitive neuroscience Berlin (CCNB), Bernstein Center  
536 für Computational Neuroscience Berlin, Universitätsmedizin Göttingen Core Facility MR-  
537 Research Göttingen, Institut für Klinische Radiologie Klinikum der Universität München,  
538 and Universitätsklinikum Tübingen MR-Forschungszentrum.

## 539 **References**

- 540 1. Alber J, Alladi S, Bae HJ, Barton DA, Beckett LA, Bell JM, et al. White matter  
541 hyperintensities in vascular contributions to cognitive impairment and dementia (VCID):  
542 Knowledge gaps and opportunities. *Alzheimer's Dement Transl Res Clin Interv*. Elsevier  
543 Inc.; 2019;5:107–17.
- 544 2. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical  
545 implications. *Lancet Neurol*. Elsevier Ltd; 2019;18:684–96.
- 546 3. Clancy U, Gilmartin D, Jochems ACC, Knox L, Doubal FN, Wardlaw JM.  
547 Neuropsychiatric symptoms associated with cerebral small vessel disease: a systematic  
548 review and meta-analysis. *The Lancet Psychiatry*. Elsevier Ltd; 2021;8:225–36.
- 549 4. Li C, Zhu Y, Ma Y, Hua R, Zhong B, Xie W. Association of Cumulative Blood Pressure  
550 With Cognitive Decline, Dementia, and Mortality. *J Am Coll Cardiol*. 2022;79:1321–35.
- 551 5. Ungvari Z, Toth P, Tarantini S, Prodan CI, Sorond F, Merkely B, et al. Hypertension-  
552 induced cognitive impairment: from pathophysiology to public health. *Nat Rev Nephrol*.  
553 Springer US; 2021;17:639–54.
- 554 6. Palta P, Albert MS, Gottesman RF. Heart health meets cognitive health: evidence on the

- 555 role of blood pressure. *Lancet Neurol*. Elsevier Ltd; 2021;20:854–67.
- 556 7. Garnier-Crussard A, Bougacha S, Wirth M, Dautricourt S, Sherif S, Landeau B, et al.  
557 White matter hyperintensity topography in Alzheimer’s disease and links to cognition.  
558 *Alzheimer’s Dement*. 2022;18:422–33.
- 559 8. Pålhaugen L, Sudre CH, Tecelao S, Nakling A, Almdahl IS, Kalheim LF, et al. Brain  
560 amyloid and vascular risk are related to distinct white matter hyperintensity patterns. *J Cereb*  
561 *Blood Flow Metab*. 2021;41:1162–74.
- 562 9. Desmarais P, Gao AF, Lanctôt K, Rogaeva E, Ramirez J, Herrmann N, et al. White matter  
563 hyperintensities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer’s  
564 disease. *Alzheimer’s Res Ther*. *Alzheimer’s Research & Therapy*; 2021;13:1–16.
- 565 10. Huynh K, Piguet O, Kwok J, Dobson-Stone C, Halliday GM, Hodges JR, et al. Clinical  
566 and Biological Correlates of White Matter Hyperintensities in Patients With Behavioral-  
567 Variant Frontotemporal Dementia and Alzheimer Disease. *Neurology*. 2021;96:e1743–54.
- 568 11. Gaubert M, Lange C, Garnier-Crussard A, Köbe T, Bougacha S, Gonneaud J, et al.  
569 Topographic patterns of white matter hyperintensities are associated with multimodal  
570 neuroimaging biomarkers of Alzheimer’s disease. *Alzheimer’s Res Ther*. *Alzheimer’s*  
571 *Research & Therapy*; 2021;13:1–11.
- 572 12. Weaver NA, Doeven T, Barkhof F, Biesbroek JM, Groeneveld ON, Kuijf HJ, et al.  
573 Cerebral amyloid burden is associated with white matter hyperintensity location in specific  
574 posterior white matter regions. *Neurobiol Aging*. Elsevier Inc; 2019;84:225–34.
- 575 13. McAleese KE, Firbank M, Dey M, Colloby SJ, Walker L, Johnson M, et al. Cortical tau  
576 load is associated with white matter hyperintensities. *Acta Neuropathol Commun*. *Acta*  
577 *Neuropathologica Communications*; 2015;3:60.
- 578 14. Englund E. Neuropathology of white matter changes in Alzheimer’s disease and vascular  
579 dementia. *Dement Geriatr Cogn Disord*. 1998;9:6–12.

- 580 15. Habes M, Sotiras A, Erus G, Toledo JB, Janowitz D, Wolk DA, et al. White matter  
581 lesions spatial heterogeneity, links to risk factors, cognition, genetics, and atrophy.  
582 *Neurology*. 2018;91:E964–75.
- 583 16. Jessen F, Spottke A, Boecker H, Brosseron F, Buerger K, Catak C, et al. Design and first  
584 baseline data of the DZNE multicenter observational study on predementia Alzheimer’s  
585 disease (DELCODE). *Alzheimer’s Res Ther. Alzheimer’s Research & Therapy*; 2018;10:1–  
586 10.
- 587 17. Morris J, Heyman A, Mohs R, Hughes M, van Belle G, Fillenbaum G, et al. Consortium  
588 to Establish a Registry on Alzheimer’s Disease (CERAD). Part I. Clinical and  
589 neuropsychological assessment of Alzheimer’s disease. *Encycl Clin Neuropsychol*.  
590 2018;940–4.
- 591 18. Molinuevo JL, Rabin LA, Amariglio R, Buckley R, Dubois B, Ellis KA, et al.  
592 Implementation of subjective cognitive decline criteria in research studies. *Alzheimer’s*  
593 *Dement*. 2017;13:296–311.
- 594 19. Jessen F, Amariglio RE, Van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A  
595 conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s  
596 disease. *Alzheimer’s Dement*. 2014;10:844–52.
- 597 20. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The  
598 diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from  
599 the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic  
600 guidelines for Alzheimer’s disease. *Alzheimer’s Dement*. 2011;7:270–9.
- 601 21. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al.  
602 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA guideline for  
603 the prevention, detection, evaluation, and management of high blood pressure in adults a  
604 report of the American College of Cardiology/American Heart Association Task Force on

- 605 Clinical pr. Hypertension. 2018.
- 606 22. Wolfsgruber S, Kleineidam L, Guski J, Polcher A, Frommann I, Roeske S, et al. Minor  
607 neuropsychological deficits in patients with subjective cognitive decline. *Neurology*.  
608 2020;95:e1134–43.
- 609 23. Papp K V., Rentz DM, Orlovsky I, Sperling RA, Mormino EC. Optimizing the preclinical  
610 Alzheimer’s cognitive composite with semantic processing: The PACC5. *Alzheimer’s*  
611 *Dement Transl Res Clin Interv*. Elsevier Inc.; 2017;3:668–77.
- 612 24. Esteban O, Birman D, Schaer M, Koyejo OO, Poldrack RA, Gorgolewski KJ. MRIQC:  
613 Advancing the automatic prediction of image quality in MRI from unseen sites. *PLoS One*.  
614 2017;12:1–21.
- 615 25. Esteban O, Blair RW, Nielson DM, Varada JC, Marrett S, Thomas AG, et al.  
616 Crowdsourced MRI quality metrics and expert quality annotations for training of humans and  
617 machines. *Sci Data* [Internet]. Springer US; 2019;6:1–7. Available from:  
618 <http://dx.doi.org/10.1038/s41597-019-0035-4>
- 619 26. Lutti A, Corbin N, Ashburner J, Ziegler G, Phillips C, Kherif F, et al. Restoring statistical  
620 validity in group analyses of motion- corrupted MRI data. *Hum Brain Mapp*. 2022;43:1973–  
621 83.
- 622 27. Alfaro-Almagro F, Jenkinson M, Bangerter NK, Andersson JLR, Griffanti L, Douaud G,  
623 et al. Image processing and Quality Control for the first 10,000 brain imaging datasets from  
624 UK Biobank. *Neuroimage*. 2018;166:400–24.
- 625 28. Bernal J, Valdés-Hernández MDC, Escudero J, Duarte R, Ballerini L, Bastin ME, et al.  
626 Assessment of perivascular space filtering methods using a three-dimensional computational  
627 model. *Magn Reson Imaging*. 2022;93:33–51.
- 628 29. Jessen F, Wolfsgruber S, Kleineindam L, Spottke A, Altenstein S, Bartels C, et al.  
629 Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory

- 630 centers. *Alzheimer's Dement.* 2022;1–11.
- 631 30. Brudfors M, Flandin G, Nachev P, Ashburner J. Flexible Bayesian Modelling for  
632 Nonlinear Image Registration Mikael. *Med Image Comput Comput Assist Interv Conf 2020*  
633 *Lect Notes Comput Sci.* Springer Nature Switzerland AG; 2020. p. 253–63.
- 634 31. Schmidt P, Wink L. LST $\square$ : A lesion segmentation tool for SPM. 2019.
- 635 32. Ashburner J, Friston KJ. Diffeomorphic registration using geodesic shooting and Gauss-  
636 Newton optimisation. *Neuroimage.* Elsevier Inc.; 2011;55:954–67.
- 637 33. Gaser C, Dahnke R. CAT - A computational anatomy toolbox for the analysis of  
638 structural MRI data. [1] C Gaser R Dahnke, "GaserHBM2016," vol 32, no 7, p 7743, 2012.  
639 2012;32:7743.
- 640 34. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al.  
641 Neuroimaging standards for research into small vessel disease and its contribution to ageing  
642 and neurodegeneration. *Lancet Neurol.* Elsevier Ltd; 2013;12:822–38.
- 643 35. Braun M, Iliff JJ. The impact of neurovascular, blood-brain barrier, and glymphatic  
644 dysfunction in neurodegenerative and metabolic diseases. 1st ed. *Int. Rev. Neurobiol.*  
645 Elsevier Inc.; 2020.
- 646 36. Brickman AM, Tosto G, Gutierrez J, Andrews H, Gu Y, Narkhede A, et al. An MRI  
647 measure of degenerative and cerebrovascular pathology in Alzheimer disease. *Neurology.*  
648 2018;91:E1402–12.
- 649 37. Cai Z, Wang C, He W, Tu H, Tang Z, Xiao M, et al. Cerebral small vessel disease and  
650 Alzheimer's disease. *Clin Interv Aging.* 2015;10:1695–704.
- 651 38. Iturria-Medina Y, Hachinski V, Evans AC. The vascular facet of late-onset Alzheimer's  
652 disease: An essential factor in a complex multifactorial disorder. *Curr Opin Neurol.*  
653 2017;30:623–9.
- 654 39. Guillaume B, Hua X, Thompson PM, Waldorp L, Nichols TE. Fast and accurate

- 655 modelling of longitudinal and repeated measures neuroimaging data. *Neuroimage* [Internet].  
656 Elsevier B.V.; 2014;94:287–302. Available from:  
657 <http://dx.doi.org/10.1016/j.neuroimage.2014.03.029>
- 658 40. Harvey A, Montezano AC, Touyz RM. Vascular biology of ageing-Implications in  
659 hypertension. *J Mol Cell Cardiol* [Internet]. The Authors; 2015;83:112–21. Available from:  
660 <http://dx.doi.org/10.1016/j.yjmcc.2015.04.011>
- 661 41. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease:  
662 Clinical Insights and Vascular Mechanisms. *Can J Cardiol* [Internet]. The Authors;  
663 2018;34:575–84. Available from: <https://doi.org/10.1016/j.cjca.2017.12.005>
- 664 42. Hair JF, Hult GTM, Ringle CM, Sarstedt M, Danks NP, Ray S. Mediation Analysis.  
665 Partial Least Squares Struct. Equ. Model. Using R. Springer, Cham; 2021.
- 666 43. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful  
667 approach to multiple testing. *J R Stat Soc Ser B. JSTOR*; 1995;289–300.
- 668 44. Charidimou A, Boulouis G, Haley K, Auriel E, Van Etten ES, Fotiadis P, et al. White  
669 matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy.  
670 *Neurology*. 2016;86:505–11.
- 671 45. Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Velow  
672 SJ. Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways  
673 Steven. *Nat Rev Neurol*. 2020;16:30–42.
- 674 46. Linn J, Halpin A, Demaerel P, Ruhland J, Giese AD, Dichgans M, et al. Prevalence of  
675 superficial siderosis in patients with cerebral amyloid angiopathy. *Neurology*. 2010;74:1346–  
676 50.
- 677 47. Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy evolution of the  
678 Boston criteria. *Stroke*. 2018;49:491–7.
- 679 48. Roseborough AD, Saad L, Goodman M, Cipriano LE, Hachinski VC, Whitehead SN.

680 White matter hyperintensities and longitudinal cognitive decline in cognitively normal  
681 populations and across diagnostic categories: A meta-analysis, systematic review, and  
682 recommendations for future study harmonization. *Alzheimer's Dement.* 2022;1–14.

683 49. Altermatt A, Gaetano L, Magon S, Bauer L, Feurer R, Gnahn H, et al. Clinical  
684 associations of T2-weighted lesion load and lesion location in small vessel disease: Insights  
685 from a large prospective cohort study. *Neuroimage.* Elsevier Ltd; 2019;189:727–33.

686 50. Kimura Y, Kitagawa K, Oku N, Kajimoto K, Kato H, Tanaka M, et al. Blood Pressure  
687 Lowering with Valsartan Is Associated with Maintenance of Cerebral Blood Flow and  
688 Cerebral Perfusion Reserve in Hypertensive Patients with Cerebral Small Vessel Disease. *J*  
689 *Stroke Cerebrovasc Dis.* Elsevier Ltd; 2010;19:85–91.

690 51. Yoshita M, Fletcher E, Harvey D, Ortega M, Martinez O, Mungas D, et al. Extent and  
691 distribution of white matter hyperintensities in normal aging, MCI, and AD. *Neurology.*  
692 2006;67:2192–8.

693 52. Keuss SE, Coath W, Nicholas JM, Poole T, Barnes J, Cash DM, et al. Associations of  $\beta$  -  
694 Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal  
695 Members of the 1946 British Birth Cohort *Neurology* ® Published Ahead of Print articles  
696 have been peer reviewed and accepted for publication . This manusc. *Neurology.* 2022;1–38.

697 53. Krell-Roesch J, Vassilaki M, Mielke MM, Kremers WK, Lowe VJ, Vemuri P, et al.  
698 Cortical  $\beta$ -amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo  
699 Clinic Study of Aging. *Transl Psychiatry.* Springer US; 2019;9.

700 54. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension Prevalence  
701 and Control Among Adults: United States, 2015-2016. *NCHS Data Brief.* 2017;1–8.

702 55. Maillard P, Seshadri S, Beiser A, Himali JJ, Au R, Fletcher E, et al. Effects of systolic  
703 blood pressure on white-matter integrity in young adults in the Framingham Heart Study: A  
704 cross-sectional study. *Lancet Neurol.* 2012;11:1039–47.



705

## 706 Figure legends

707 **Figure 1. Model investigating direct and indirect (via WMH) effects of hypertension and A $\beta$  positivity on**  
708 **cognition.**

709 Here we seek to understand whether subjects with arterial hypertension or A $\beta$  positive status have worse  
710 cognitive performance at baseline (baseline memory, executive function, and PACC5 scores) and outcomes over  
711 time ( $\Delta$ PACC5). Because both the A $\beta$  and vascular pathologies may exacerbate the formation of WMH and  
712 these, in turn, may also contribute to brain dysfunction and poor cognitive outcomes [5,6,40,41], we also test for  
713 an indirect mediating effect of hypertension and A $\beta$  positivity on cognitive performance via regional WMH  
714 volumes. We adjusted such models for age, sex, education, mean background intensity, and TICV, as described  
715 in ‘Covariates, confounders, and data transformation’.

716

717 **Figure 2. Posterior WMH probability is associated with both history of arterial hypertension and A $\beta$**   
718 **positivity.**


719 *Analysis.* We examined the relationship between WMH segmentation maps (outcome) and arterial hypertension  
720 and A $\beta$  positivity (factors) at a voxel level via 2x2 ANCOVA. We accounted for the effects of age, sex,  
721 education, mean background intensity, and total intracranial volume. We used an explicit mask to constrain the  
722 analysis to voxels in which data for at least five patients were available. *Illustration.* Glass brain projections  
723 display regions where we found evidence for a link between WMH probability and hypertension and A $\beta$   
724 positivity (top and middle rows, respectively). In the bottom row, we coloured regions blue if  $T$  values for  
725 hypertension were greater than for A $\beta$  positivity and gold otherwise. We thresholded contrast maps at 5% and  
726 adjusted  $p$ -values for FDR. *Findings.* Subjects with hypertension had significantly greater WMH volumes  
727 throughout the whole brain than those with normotension (peak: superior longitudinal fasciculus,  $xyz_{MNI} = [32, -$   
728  $1, 18]$ ,  $T = 3.88$ ,  $DoF = [1.0, 367.0]$ ,  $p_{FDR} = 0.015$ ). Moreover, WMH volume was significantly higher in  
729 subjects A $\beta$  positivity versus negativity in posterior regions of the brain, particularly in segments of the forceps  
730 major and inferior fronto-occipital fasciculus ( $xyz_{MNI} = [30, -58, 4]$ ,  $T = 5.20$ ,  $DoF = [1.0, 367.0]$ ,  $p_{FDR} = 0.001$ ).

731


732 **Figure 3. WMH volume is associated with worse baseline cognitive performance and accelerated decline**  
733 **over time.**

734 *Analysis.* We used multiple linear regression with WMH segmentation maps as the dependent variable and  
735 cognitive performance as the independent variable. We accounted for the effects of hypertension, A $\beta$  positivity,  
736 age, sex, education, mean background intensity, and total intracranial volume. We used an explicit mask to  
737 constrain the analysis to voxels in which data for at least five patients were available. We thresholded contrast  
738 maps at 5% and adjusted  $p$ -values for FDR. *Illustration.* Regression results with memory (top left), executive  
739 function (bottom left), PACC5 (top right), and  $\Delta$ PACC5 (bottom right) as independent variables. *Findings.* We  
740 found WMH to be significantly associated with worse cognitive performance at baseline and sharper decline  
741 within a three-year period. Such relationships were consistently evident around portions of the anterior thalamic  
742 radiation neighbouring the thalamus (memory:  $xyz_{MNI} = [-8, -1, 3]$ ,  $T = 7.00$ ,  $DoF = [1.0, 366.0]$ ,  $p_{FDR} = 1.44 \times 10^{-5}$ ;  
743 executive:  $xyz_{MNI} = [-9, 0, 5]$ ,  $T = 6.74$ ,  $DoF = [1.0, 366.0]$ ,  $p_{FDR} = 2.85 \times 10^{-5}$ ; PACC5:  $xyz_{MNI} = [-8, 1, 4]$ ,  $T =$   
744  $7.20$ ,  $DoF = [1.0, 366.0]$ ,  $p_{FDR} = 8.43 \times 10^{-6}$ ;  $\Delta$ PACC5:  $xyz_{MNI} = [-7, 2, 2]$ ,  $T = 4.53$ ,  $DoF = [1.0, 217.0]$ ,  $p_{FDR} =$   
745  $5.12 \times 10^{-3}$ ). Frontal and occipital WMH also coincided with a faster cognitive decline (frontal peak at the level  
746 of the genu of the corpus callosum:  $xyz_{MNI} = [-1, 23, 4]$ ,  $T = 5.19$ ,  $DoF = [1.0, 217.0]$ ,  $p_{FDR} = 1.37 \times 10^{-3}$ ; occipital  
747 peak at the level of the forceps major and inferior fronto-occipital longitudinal fasciculus:  $xyz_{MNI} = [17, -81, 2]$ ,  
748  $T = 4.69$ ,  $DoF = [1.0, 217.0]$ ,  $p_{FDR} = 1.23 \times 10^{-2}$ ).






## Regions associated with arterial hypertension



## Regions associated with A $\beta$ positivity




## Maximum effect




■ T value of hypertension > A $\beta$  positivity

■ T value of A $\beta$  positivity > hypertension


Baseline memory



Baseline executive



Baseline PACCS



$\Delta$ PACCS

